Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie för att utvärdera säkerheten och tolerabiliteten av Dapirolizumab Pegol hos studiedeltagare med systemisk lupus erythematosus

14 oktober 2026 uppdaterad av: UCB Biopharma SRL

En multicenter, öppen förlängningsstudie för att utvärdera den långsiktiga säkerheten och tolerabiliteten av Dapirolizumab Pegol-behandling hos studiedeltagare med systemisk lupus erythematosus

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

Studieöversikt

Status

Anmälan via inbjudan

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Beräknad)

760

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Buenos Aires, Argentina
        • Sl0046 60002
      • Mendoza, Argentina
        • Sl0046 60029
      • Quilmes, Argentina
        • Sl0046 60003
      • Quilmes, Argentina
        • Sl0046 60022
      • San Juan, Argentina
        • Sl0046 60011
      • San Miguel de Tucumán, Argentina
        • Sl0046 60014
      • Brussels, Belgien
        • Sl0046 40123
      • Plovdiv, Bulgarien
        • Sl0046 40189
      • Sofia, Bulgarien
        • Sl0046 40380
      • Santiago, Chile
        • Sl0046 60018
      • Santiago, Chile
        • Sl0046 60015
      • Barranquilla, Colombia
        • Sl0046 60013
      • Barranquilla, Colombia
        • Sl0046 60019
      • Bogotá, Colombia
        • Sl0046 60006
      • Bogotá, Colombia
        • Sl0046 60027
      • Bucaramanga, Colombia
        • Sl0046 60016
      • Chía, Colombia
        • Sl0046 60007
      • Montería, Colombia
        • Sl0046 60031
      • Davao City, Filippinerna
        • Sl0046 20182
      • Makati, Filippinerna
        • Sl0046 20181
    • Alabama
      • Birmingham, Alabama, Förenta staterna, 35294
        • Sl0046 50140
    • Arizona
      • Avondale, Arizona, Förenta staterna, 85392
        • Sl0046 50058
      • Glendale, Arizona, Förenta staterna, 85306
        • Sl0046 50662
      • Phoenix, Arizona, Förenta staterna, 85032
        • Sl0046 50052
      • Tucson, Arizona, Förenta staterna, 85704
        • Sl0046 50328
    • California
      • Beverly Hills, California, Förenta staterna, 90210
        • Sl0046 50383
      • La Palma, California, Förenta staterna, 90623-1730
        • Sl0046 50275
      • San Leandro, California, Förenta staterna, 94578
        • Sl0046 50316
    • Colorado
      • Denver, Colorado, Förenta staterna, 80230
        • Sl0046 50339
    • Florida
      • Brandon, Florida, Förenta staterna, 33511
        • Sl0046 50239
      • Gainesville, Florida, Förenta staterna, 32610
        • Sl0046 50362
      • Miami, Florida, Förenta staterna, 33172
        • Sl0046 50681
      • Ormond Beach, Florida, Förenta staterna, 32174
        • Sl0046 50059
      • Plantation, Florida, Förenta staterna, 33324
        • Sl0046 50324
      • Tampa, Florida, Förenta staterna, 33606
        • Sl0046 50329
      • Tampa, Florida, Förenta staterna, 33618
        • Sl0046 50698
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30303
        • Sl0046 50368
    • Idaho
      • Idaho Falls, Idaho, Förenta staterna, 83404
        • Sl0046 50240
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60616
        • Sl0046 50699
    • Kentucky
      • Hopkinsville, Kentucky, Förenta staterna, 42240-1746
        • Sl0046 50474
    • Louisiana
      • Lake Charles, Louisiana, Förenta staterna, 70605
        • Sl0046 50285
      • New Orleans, Louisiana, Förenta staterna, 70112
        • Sl0046 50660
    • Maryland
      • Hagerstown, Maryland, Förenta staterna, 21740
        • Sl0046 50015
    • Michigan
      • Detroit, Michigan, Förenta staterna, 48201
        • Sl0046 50219
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89128
        • Sl0046 50273
    • New York
      • Canton, New York, Förenta staterna, 13617
        • Sl0046 50366
      • Manhasset, New York, Förenta staterna, 11030
        • Sl0046 50264
      • New York, New York, Förenta staterna, 10032
        • Sl0046 50334
    • North Carolina
      • Charlotte, North Carolina, Förenta staterna, 28211
        • Sl0046 50238
    • Pennsylvania
      • Hershey, Pennsylvania, Förenta staterna, 17033
        • Sl0046 50147
    • Tennessee
      • Jackson, Tennessee, Förenta staterna, 38305
        • Sl0046 50001
    • Texas
      • Bellaire, Texas, Förenta staterna, 77401
        • Sl0046 50738
      • Colleyville, Texas, Förenta staterna, 76034
        • Sl0046 50418
    • West Virginia
      • Beckley, West Virginia, Förenta staterna, 25801
        • Sl0046 50050
      • Athens, Grekland
        • Sl0046 40378
      • Athens, Grekland
        • Sl0046 40501
      • Crete, Grekland
        • Sl0046 40377
      • Larissa, Grekland
        • Sl0046 40507
      • Catania, Italien
        • Sl0046 40084
      • Milan, Italien
        • Sl0046 40448
      • Nagoya, Japan
        • Sl0046 20287
      • Calgary, Kanada
        • Sl0046 50374
      • Edmonton AB, Kanada
        • Sl0046 50337
      • Rimouski, Kanada
        • Sl0046 50259
      • Toronto, Kanada
        • Sl0046 50045
      • Beijing, Kina
        • Sl0046 20128
      • Changchun, Kina
        • Sl0046 20291
      • Guangzhou, Kina
        • Sl0046 20019
      • Guilin, Kina
        • Sl0046 20290
      • Shanghai, Kina
        • Sl0046 20020
      • Shantou, Kina
        • Sl0046 20346
      • Suzhou, Kina
        • Sl0046 20204
      • Tianjin, Kina
        • Sl0046 20136
      • Wenzhou, Kina
        • Sl0046 20025
      • Wuhan, Kina
        • Sl0046 20180
      • Yangzhou, Kina
        • Sl0046 20273
      • Zhengzhou, Kina
        • Sl0046 20132
      • Chihuahua City, Mexiko
        • Sl0046 50317
      • Cuernavaca, Mexiko
        • Sl0046 50250
      • Guadalajara, Mexiko
        • Sl0046 50249
      • León, Mexiko
        • Sl0046 50271
      • Monterrey, Mexiko
        • Sl0046 50251
      • Mérida, Mexiko
        • Sl0046 50252
      • Lima, Peru
        • Sl0046 60023
      • Lima, Peru
        • Sl0046 60009
      • Bialystok, Polen
        • Sl0046 40482
      • Bydgoszcz, Polen
        • Sl0046 40119
      • Katowice, Polen
        • Sl0046 40398
      • Krakow, Polen
        • Sl0046 40502
      • Lublin, Polen
        • Sl0046 40151
      • Poznan, Polen
        • Sl0046 40044
      • Poznan, Polen
        • Sl0046 40090
      • Warsaw, Polen
        • Sl0046 40097
      • Warsaw, Polen
        • Sl0046 40098
      • Wroclaw, Polen
        • Sl0046 40397
      • Wroclaw, Polen
        • Sl0046 40481
      • Caguas, Puerto Rico
        • Sl0046 50671
      • Galati, Rumänien
        • Sl0046 40382
      • Belgrade, Serbien
        • Sl0046 40393
      • Belgrade, Serbien
        • Sl0046 40461
      • Belgrade, Serbien
        • Sl0046 40730
      • Novi Sad, Serbien
        • Sl0046 40392
      • Barcelona, Spanien
        • Sl0046 40160
      • Málaga, Spanien
        • Sl0046 40341
      • Sabadell, Spanien
        • Sl0046 40101
      • Vigo, Spanien
        • Sl0046 40099
      • Incheon, Sydkorea
        • Sl0046 20108
      • Seoul, Sydkorea
        • Sl0046 20104
      • Taichung, Taiwan
        • Sl0046 20113
      • Taichung, Taiwan
        • Sl0046 20142
      • Taipei, Taiwan
        • Sl0046 20095
      • Taiyuan, Taiwan
        • Sl0046 20082
      • Prague, Tjeckien
        • Sl0046 40066
      • Cologne, Tyskland
        • Sl0046 40386
      • Freiburg im Breisgau, Tyskland
        • Sl0046 40072
      • Herne, Tyskland
        • Sl0046 40027
      • Leipzig, Tyskland
        • Sl0046 40078
      • Tübingen, Tyskland
        • Sl0046 40402
      • Vogelsang-gommern, Tyskland
        • Sl0046 40715
      • Budapest, Ungern
        • Sl0046 40412
      • Debrecen, Ungern
        • Sl0046 40411
      • Szeged, Ungern
        • Sl0046 40031
      • Székesfehérvár, Ungern
        • Sl0046 40499

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

16 år och äldre (Barn, Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment
  • The participant completed one of the parent studies within 4 weeks prior to entry to this study

Exclusion Criteria:

- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Dapirolizumab pegol

Subjects will receive dapriolizumab pegol throughout the Treatment Period.

Subjects will receive dapirolizumab pegol at prespecified time-points.

Andra namn:
  • CDP7657
  • DZP

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of treatment-emergent adverse events (TEAEs) during the study
Tidsram: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.

From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
Incidence of serious treatment-emergent adverse events during the study
Tidsram: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

A serious treatment-emergent adverse event (serious TEAE) is any untoward medical occurrence that at any dose:

  • Results in death
  • Is life-threatening
  • Requires in patient hospitalisation or prolongation of existing hospitalisation
  • Results in persistent disability/incapacity
  • Is a congenital anomaly or birth defect
  • Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above
From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuation
Tidsram: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, and leading to permanent drug discontinuation whether or not these events are related to study treatment.

From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 24
Tidsram: Week 24

BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

Week 24
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 52
Tidsram: Week 52

BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

Week 52
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 104
Tidsram: Week 104

BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A since previous visit in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).

Week 104
Achievement of LLDAS at ≥50% of all visits
Tidsram: From Baseline (Day 1) until End of Treatment (Week 104)

Low lupus disease activity state (LLDAS) is defined as:

  • No significant disease activity as per SLEDAI-2K and BILAG 2004 (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever)
  • No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit
  • PGA ≤33 mm
  • Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day
  • Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
From Baseline (Day 1) until End of Treatment (Week 104)
Achievement of BICLA response at Week 24
Tidsram: Week 24

A study participant is considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following is fulfilled:

  1. British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
  2. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
  3. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale

The parent studies Baseline will be used as reference point.

Week 24
Achievement of BICLA response at Week 52
Tidsram: Week 52

A study participant is considered to be a BICLA responder if all of the following is fulfilled:

  1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
  2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
  3. No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale

The parent studies Baseline will be used as reference point.

Week 52
Achievement of BICLA response at Week 104
Tidsram: Week 104

A study participant is considered to be a BICLA responder if all of the following is fulfilled:

  1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and
  2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and
  3. No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale

The parent studies Baseline will be used as reference point.

Week 104

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: UCB Cares, 001 844 599 2273 (UCB)

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

27 juli 2021

Primärt slutförande (Beräknad)

7 augusti 2030

Avslutad studie (Beräknad)

7 augusti 2030

Studieregistreringsdatum

Först inskickad

14 juli 2021

Först inskickad som uppfyllde QC-kriterierna

14 juli 2021

Första postat (Faktisk)

26 juli 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

14 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • SL0046
  • 2019-003409-83 (EudraCT-nummer)
  • U1111-1293-7098 (Annan identifierare: World Health Organization (WHO))
  • 2023-506368-14 (Registeridentifierare: EU Clinical Trials)
  • 2023 (U.S.S. NIH-anslag/kontrakt)
  • 2019 (U.S.S. NIH-anslag/kontrakt)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Tidsram för IPD-delning

Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Kriterier för IPD Sharing Access

Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera